Analysis of satisfaction with drug therapy for anemia in patients with stage 5 chronic kidney disease on hemodialysis

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. In modern scientific literature, assessment of patient satisfaction with treatment is considered as an important method for assessing the results of treatment from the standpoint of the patient. Objective. Comprehensive analysis of satisfaction with drug therapy for anemia in patients with stage 5 chronic kidney disease (CKD) on hemodialysis (HD), taking into account the medical and demographic characteristics of patients, achieved Hb levels, adherence to treatment and health-related quality of life (QoL). material and methods. in the period from august to November 2021, a survey of patients with stage 5 ckd on hd was conducted. the total number of respondents was 515 patients. the dtsq (modified) and kdqol questionnaires were used to assess satisfaction with treatment and QoL of patients. results. a significant positive correlation between patient satisfaction with drug therapy for anemia, hb level, adherence to treatment, quality of life, material wealth and living conditions of patients was found. Conclusion. Comprehensive assessment of satisfaction with drug therapy for anemia among patients with stage 5 ckd on hd is of great importance in the evaluation and selection of effective methods of treatment

Толық мәтін

Рұқсат жабық

Авторлар туралы

Oleg Kotenko

Moscow City Scientific and Practical Center for Nephrology and Transplanted Kidney Pathology; City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: olkotenko@yandex.ru
Cand.Sci. (Med.), Deputy Chief Physician for Nephrology, City Clinical Hospital № 52 of the Moscow Healthcare Department, Chief External Expert in Nephrology of the Moscow Healthcare Department Moscow, Russia

Lyubov Abolyan

Sechenov University

Email: labolyan@mail.ru
Dr.Sci. (Med.), Professor at the Department of Public Health and Healthcare named after. N.A Semashko Moscow, Russia

Vladislav Kuteinikov

Sechenov University

Email: vladislav864vlad@list.ru
Postgraduate Student at the Department of Public Health and Healthcare named after N.A. Semashko Moscow, Russia

Vladimir Vinogradov

Research Institute of care Organization and Medical Management of the Moscow Healthcare Department

Email: vino-gradoff@yandex.ru
Head of the Consultative and Diagnostic Nephrology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department, Specialist at the Organizational and Methodological Department for Nephrology, Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department Moscow, Russia

Ekaterina Dorofeeva

Moscow City Scientific and Practical Center for Nephrology and Transplanted Kidney Pathology, City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: egdorofeeva@bk.ru
Nephrologist, Consultative and Diagnostic Nephrology Department Moscow, Russia

Әдебиет тізімі

  1. Шилов Е.М., Шилова М.М., Румянцева Е.И. и др. Состояние нефрологической службы в Российской Федерации: заместительная почечная терапия в период с 2017 по 2021 г. Клиническая нефрология. 2022;14(1):6-15. doi: 10.18565/nephrology.2022.1.6-15. @@Shilov E.M., Shilova M.M., Rumyanseva E.I., et al. State of nethrological service in the Russian Fedeation: renal replacement therapy in the period from 2017 to 2021. Clinical Nephrology. 2022;2:6-15 (In Russ.)
  2. Шило В.Ю., Хасабов Н.Н. Анемия при хронической болезни почек. Лечащий врач. 2008;1:56-61. @@ Shilo V.Yu., Hasabov N.N. Anemiya pri hronicheskoj boleznipochek. Lech. Vrach. 2008;1:56-61 (In Russ.)
  3. Милованов Ю.С., Милованова Л.Ю., Козловская Л.В. Нефрогенная анемия: патогенез, прогностическое значение, принципы лечения. Клиническая нефрология. 2010;6:7-18. @@ Milovanov Yu.S., Milovanova L. Yu., Kozlovskaya L.V Nefrogennaya anemiya: patogenez, prognosticheskoe znachenie, principy lecheniya. Clinical Nephrology. 2010;6:7-18 (In Russ.)
  4. Михайлова Н.А. Возможности оптимизации ЭПО-терапии у пациентов сренальной анемией. Эффективная фармакотерапия. 2021;17(3):24-32. doi: 10.33978/2307-3586-2021-17-3-24-32. @@Mihajlova N.A. Vozmozhnosti optimizacii EPO-terapii u pacientov s renal’noj anemiej. Effektivnaya Farmakoterapiya. 2021;17(3):24-32 (In Russ.)
  5. Pisoni R.L., Bragg-Gresham J.L., Young E.W., et al. Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am. J. Kidney Dis 2004;44:94-111.
  6. Stauffer M.E., Fan T. Prevalence of Anemia in Chronic Kidney Disease in the United States. PLoS ONE. 2014;9(1):e84943. Doi: 10.1371/ journal. pone.0084943.
  7. Akizawa T., Okumura H., Alexandre A.F., et al. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Ther. Apher. Dial. 2018;22(5):444-56. doi: 10.1111/1744-9987.12712.
  8. Шутов Е.В., Горелова Е.Н., Сороколетов С.М. Ингибиторы пролилгидроксилазы больных с хронической болезнью почек. Эффективная фармакотерапия. 2022;18(3):22-8. doi: 10.33978/2307-3586-2022-18-3-22-28. @@ Shutov E.V., Gorelova E.N., Sorokoletov S.M. Ingibitory prolilgidroksilazy induciruemogo gipoksiej faktora v lechenii anemii bol’nyh s hronicheskoj bolezn’yu pochek. Effektivnaya Farmakoterapiya. 2022;18(3):22-8 (In Russ.)
  9. Eriksson D., Goldsmith D., Teitsson S., et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC. Nephrol. 2016;17:97.
  10. Hanna R.M., Streja E., Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv. Ther. 2021;38(1):52-75. doi: 10.1007/s12325-020-01524-6.
  11. Spinowitz B., Pecoits-Filho R., Winkelmayer W.C., et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J. Med. Econ. 2019;22(6):593-604. doi: 10.1080/13696998.2019.1588738.
  12. Мельник А.А. Гипоксией индуцированный фактор для лечения анемии при хронической болезни почек. Pocki. 2018;7(4):311-21. doi: 10.22141/23071257.7.4.2018.148522. @@Melnik A.A. Gipoksiej inducirovannyj faktor dlya lecheniya anemii pri hronicheskoj bolezni pochek. Pocki. 2018;7(4):311-21 (In Russ.)
  13. Hasegawa T., Bragg-Gresham J.L. , Pisoni R.L., et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int. 2011;79:340-46.
  14. Moyneur E., Bookhart B.K., Mody S.H., et al. The economic impact of predialisis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer’s perspective. Dis. Manag. 2008;11:49-58.
  15. Lui J., Guo H., Gilbertson D., et al. Association of anemia persistency with medical expenditures in Medicare ESRD patient on dialysis. Ther. Clin. Risk Manag. 2009;5:319-30.
  16. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. Под ред. Ю.Л. Шевченко. М., 2021. 664 с. @@ Novik A.A., Ionova T.I.Rukovodstvo po issledovaniyu kachestva zhizni v medicine. Ed. Yu.L. Shevchenko. M., 2021. 664p. (In Russ.)
  17. Cangini G, Rusolo D., Cappuccilli M., et al. Evolution of the concept of quality of life in the population in end stage renal disease. A systematic review of the literature. Clin. Ter. 2019;170(4):e301-20. doi: 10.7417/CT.2019.2152.
  18. Mathias S.D., Blum S.I., Sikirica V., et al. Symptoms and impacts in anemia of chronic kidney disease. Patient Rep. Outcomes. 2020;4(1):64. Doi: 10.1186/ s41687-020-00215-8.
  19. Bradley C. Diabetes Treatment Satisfaction Questionnaire (DTSQ) In: Bradley C, ed. Handbook of psychology and diabetes. Chur (Switzerland): Harwood Academic Publishers, 1994.
  20. Barendse S.M. Speight J., Bradley C. The Renal Treatment Satisfaction Questionnaire (RTSQ): a measure of satisfaction with treatment for chronic kidney failure. Am. J. Kidney Dis. 2005;45(3):572-79.
  21. Woodcock A., Bradley C. Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version. Value Health. 2006;9(5):320-33. doi: 10.1111/j.1524-4733.2006.00121.x.
  22. Saisho Y. Use of Diabetes Treatment Satisfaction Questionnaire in diabetes care: importance of patient-reported outcomes.Int. J. Environ. Res. Public Health. 2018;15(5):947. doi: 10.3390/ijerph15050947
  23. Бобыкин Е.В., Коротких С.А., Нерус И.А., Морозова О.В. Удовлетворенность лечением пациентов с неоваскулярной возрастной макулярной дегенерацией, получающих антиангиогенную терапию. PMK; 2019;(2):11-4. doi: 10.17238/PmJ1609-1175.2019.2.14-18. @@Bobykin E.V., Korotkih S.A., Nerus I.A., Morozova O.V. Udovletvorennost’ lecheniem pacientov s neovaskulyarnoj vozrastnoj makulyarnoj degeneraciej, poluchayushchih antiangiogennuyu terapiyu. PMJ. 2019;(2):11-4 (In Russ.)
  24. Калашникова М.Ф., Бондарева И.Б., Лиходей Н.В., Сыч Ю.П. Анализ удовлетворенности лечением и приверженности терапии пациентов с сахарным диабетом 2-го типа. Альманах клинической медицины. 2020;48(7):476-86. doi: 10.18786/2072-0505-2020-48-048. @@Kalashnikova M.F., Bondareva I.B., Lihodej N.V., Sych YU.P. Analiz udovletvorennosti lecheniem i priverzhennosti terapii pacientov s saharnym diabetom 2-go tipa. Al’manah klinicheskoj mediciny. 2020;48(7):476-86 (In Russ.)
  25. Hays R.D., Kallich J., Mapes D.L., et al. Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3. A Manual for Use and Scoring. P-7994. Santa Monica, CA: RAND 1997:1-39.
  26. RAND Health Care. Kidney Disease Quality of Life Instrument (KDQOL). The KDQOL-SFTMv1.3 Survey. Accessed September 23, 2022. https://www.rand. org/health-care/surveys_tools/kdqol.html.
  27. Васильева И.А. Российская версия опросника Kidney Disease and Quality of Life Short Form (KDQOL-SF™) - ценного диагностического инструмента оценки качества жизни больных на диализе. Нефрология. 2007;11(1):64-70 @@Vasilieva I.A. Rossijskaya versiya oprosnika Kidney Disease and Quality of Life Short Form (KDQOL-SF™) - cennogo diagnosticheskogo instrumenta ocenki kachestva zhizni bol’nyh na dialize. Nefrol. 2007;11(1):64-70(In Russ.)
  28. Joly D., Quinn J., Mokiou S., O’Reilly K., et al. Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe. BMC. Nephrol. 2020;21(1):298. doi: 10.1186/s12882-020-01927-1.
  29. Васильева И.А., Смирнов А.В. Оценка качества жизни больных на гемодиализе при помощи опросника KDQOL-SFTM. Нефрология. 2017;21(4):55- 60. Doi: 10.2488 4/1561 -6274-2017-21-4-55-60. @@Vasilieva IA, Smirnov AV. Evaluation of quality of life hemodialisys patient using the KDQOL-SFTM questionnaire. Nefrologiya. 2017;21(4):55-60 (In Russ.)
  30. Joly D., Quinn J., Mokiou S., O’Reilly K., et al. Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe. BMC. Nephrol. 2020;21(1):298. doi: 10.1186/s12882-020-01927-1.
  31. Atkinson M.J., Sinha A., Hass S.L., et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
  32. Киштович А.В., Курбатова К.А., Ионова Т.И. Апробация русскоязычной версии опросника удовлетворенности лечением диабета DTSQ. Вестн. Межнационального центра исследования качества жизни. 2015;25-26:51-5. @@Kishtovich A.V., Kurbatova K.A., Ionova T.I. Aprobaciya russkoyazychnoj versii oprosnika udovletvorennosti lecheniem diabeta DTSQ. Vestn. Mezhnacional’nogo Centra Issled. Kachest. Zhizni. 2015;25-26:51-5 (In Russ.)
  33. Кутейников В.Ю., Абольян Л.В. Опыт использования русскоязычной версии опросника DTSQ для оценки удовлетворенности лечением анемии среди пациентов с хронической почечной недостаточностью (ХПН) на гемодиализе. Кардиоваскулярная терапия и профилактика. 2022;21(2S):65. @@Kutejnikov V.Yu., Abol’yan L.V. Opyt ispol’zovaniya russkoyazychnoj versii oprosnika DTSQ dlya ocenki udovletvorennosti lecheniem anemii sredi pacientov s hronicheskojpochechnoj nedostatochnost’yu (HPN) na gemodialize. Cardiovaskul. Ter. Profil. 2022;21(2S):65 (In Russ.)
  34. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82. @@Clinical recommendations. Chronic kidney disease (CKD). Nephrol. (Saint-Petersburg). 2021;25(5):10-82 (In Russ.)
  35. Клинические рекомендации - Анемия при хронической болезни почек - 2020-2021-2022 (31.05.2021). Утверждены Минздравом РФ. Ссылка активна на 26.04.2022. http://disuria.ru/_ld/11/1126_kr20D63p8MZ.pdf. @@Clin. Rekomend. - Anemiya pri hronicheskoj bolezni pochek - 20202021-2022 (31.05.2021) (In Russ.)
  36. Котенко О.Н., Абольян Л.В., Кутейников В.Ю. и др. Медико-социальные характеристики и качество жизни пациентов с хронической болезнью почек (ХБП), получающих заместительную почечную терапию методом программного гемодиализа. Нефрология и диализ. 2021;23(4):508-23. doi: 10.28996/2618-9801-2021-4-508-523. @@Kotenko O.N., Abolyan L.V., Kuteinikov V.Yu., et al. Medical and social Characteristics and quality of life in patients with chronic kidney disease (CKD) receiving program hemodialysis. Nefrologiya i dializ. 2021;23(4):508-23. (In Russ.)

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>